Vimta Labs Limited , a leading contract research and testing organization, has reported robust financial results for the fourth quarter and fiscal year 2024-25, along with several key announcements that signal confidence in the company's growth trajectory.

Q4 and FY25 Financial Highlights

Fourth Quarter Ended March 31, 2025

• Total income: ₹960.81 crore, up 31.4% year-over-year
• EBITDA: ₹346.80 crore, with a margin of 36.1%
• Net profit: ₹183.19 crore, representing a 31.2% increase from the previous year

Fiscal Year 2024-25

• Total income: ₹3,482.22 crore, growing 19.1% compared to FY24
• EBITDA: ₹1,261.90 crore, with a margin of 36.2%
• Net profit: ₹667.55 crore, showing a significant 36.8% rise year-over-year

Shareholder Rewards and Capital Structure

The Board of Directors has recommended:

1. A final dividend of ₹2 per equity share for FY 2024-25, subject to shareholder approval.
2. A bonus issue in the ratio of 1:1, meaning shareholders will receive one bonus share for every share held.

Strategic Expansion into Biologics

Vimta Labs announced its foray into Biologics Contract Research and Development activities, subject to shareholder approval. The company plans to invest approximately ₹50 crore in this new venture.

Operational Highlights

During FY25, Vimta Labs achieved several operational milestones:

• Successful regulatory audits from various authorities, including USFDA and European Medicines Agency
• Entry into clinical trial services
• Relocation of the Pune food testing lab to Nashik
• Capacity expansion with an additional 200,000 sq. ft. of modern laboratory space at the Life Sciences Facility
• Merger of EMTAC Laboratories Private Limited, a wholly-owned subsidiary

Financial Position

As of March 31, 2025, Vimta Labs reported:

Management Commentary

Harita Vasireddi, Managing Director of Vimta Labs, commented: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements."

She added, "We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain."

Outlook

With its strong financial performance, strategic expansion plans, and focus on high-growth areas in the contract research and testing sector, Vimta Labs appears well-positioned for continued growth. The company's investments in talent, infrastructure, and business development are expected to strengthen its platform for long-term value creation in the evolving healthcare and life sciences landscape.

Vimta Labs Limited , a leading contract research and testing organization, has reported robust financial results for the fiscal year 2024-25 (FY25) and announced ambitious growth plans for the future.

Financial Highlights

For the fiscal year ended March 31, 2025, Vimta Labs reported:

• Total income of Rs. 3,482.22 crore, up 19.1% from Rs. 2,923.05 crore in FY24
• EBITDA of Rs. 1,261.90 crore, a 29.1% increase from Rs. 977.50 crore in the previous year
• Net profit of Rs. 667.55 crore, showing a significant 36.8% growth from Rs. 488.11 crore in FY24
• Earnings per share (EPS) rose to Rs. 30.02, compared to Rs. 22.04 in FY24

Strategic Developments

Vimta Labs has set an ambitious revenue target of exceeding Rs. 500 crore by the financial year 2025-26, demonstrating the company's confidence in its growth trajectory and market position.

The company's board has recommended several key initiatives:

1. A final dividend of Rs. 2 per equity share for FY 2024-25.
2. A bonus share issue in the ratio of 1:1, subject to shareholder approval.
3. Foray into Biologics Contract Research and Development activities (CDMO), with an estimated investment of Rs. 50 crore.

Expansion into Biologics CDMO

Vimta Labs' entry into Biologics Contract Research and Development is a strategic move to capitalize on the growing CDMO market for biologics and peptides. This expansion is expected to strengthen the company's service portfolio for the biopharmaceutical industry and accelerate business growth.

Operational Highlights

The company reported several operational achievements during FY25:

• Successful regulatory audits from various authorities, including USFDA, European Medicines Agency, and others.
• Expansion of clinical trial services.
• Relocation of the Pune food testing lab to Nashik to be closer to agri-produce regions.
• Addition of approximately 200,000 sq. ft. of modern laboratory spaces at the Life Sciences Facility.

Management Commentary

Harita Vasireddi, Managing Director of Vimta Labs, commented on the results: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation."

Future Outlook

With its strategic expansion into biologics, ongoing capacity enhancements, and strong financial performance, Vimta Labs appears well-positioned to achieve its ambitious revenue target and capitalize on the growing demand in the contract research and testing market.

Investors and industry observers will be watching closely to see how Vimta Labs executes its growth strategy and maintains its momentum in the coming years.